Linked Life Data

14695221

Source:http://linkedlifedata.com/resource/pubmed/id/14695221

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14695221rdf:typepubmed:Citationlld:pubmed
pubmed-article:14695221lifeskim:mentionsumls-concept:C0021083lld:lifeskim
pubmed-article:14695221lifeskim:mentionsumls-concept:C0018183lld:lifeskim
pubmed-article:14695221lifeskim:mentionsumls-concept:C0022686lld:lifeskim
pubmed-article:14695221lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:14695221lifeskim:mentionsumls-concept:C1134651lld:lifeskim
pubmed-article:14695221lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:14695221lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:14695221pubmed:issue24lld:pubmed
pubmed-article:14695221pubmed:dateCreated2003-12-25lld:pubmed
pubmed-article:14695221pubmed:abstractTextThe tumor-killing mechanisms available to monoclonal antibodies (mAbs; e.g., antagonism of growth factor receptors, antibody-dependent cell-mediated cytotoxicity) limit efficacy. Previous studies suggested that i.v. beta-glucan might function as an adjuvant for antitumor mAbs. beta- Glucan had been shown to function via the iC3b-receptor complement receptor 3 (CR3; CD11b/CD18) thereby enhancing leukocyte killing of tumor cells coated with iC3b via naturally occurring antitumor antibodies. Therapy with beta-glucans was limited by levels of natural antibodies and by tumor escape through elimination of antigen-positive cells. Accordingly, it was hypothesized that beta-glucan responses could be improved by combined administration with antitumor mAbs. Five tumor models were explored in BALB/c or C57Bl/6 mice using tumors that expressed either high levels of naturally occurring antigens (e.g., G(D2) ganglioside) or recombinant human MUC1. In comparison with antitumor mAb or beta-glucan alone, combined treatment with mAb plus beta-glucan produced significantly greater tumor regression in all models that included mammary, s.c., and hepatic tumors. Tumor-free survival only occurred in models that incorporated stable expression of the target antigen. beta-Glucan enhancement of the mAb tumoricidal response did not occur in mice deficient in either leukocyte CR3 (CD11b(-/-)) or serum C3, confirming the requirement for CR3 on leukocytes and iC3b on tumors. Granulocytes appeared to be primarily responsible for tumoricidal activity, because beta-glucan therapeutic responses did not occur in granulocyte-depleted mice. These data suggest that the therapeutic efficacy of mAbs known to activate complement (e.g., Herceptin, Rituxan, and Erbitux) could be significantly enhanced if they were combined with beta-glucan.lld:pubmed
pubmed-article:14695221pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695221pubmed:languageenglld:pubmed
pubmed-article:14695221pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695221pubmed:citationSubsetIMlld:pubmed
pubmed-article:14695221pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695221pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695221pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695221pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695221pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695221pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695221pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695221pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695221pubmed:statusMEDLINElld:pubmed
pubmed-article:14695221pubmed:monthDeclld:pubmed
pubmed-article:14695221pubmed:issn0008-5472lld:pubmed
pubmed-article:14695221pubmed:authorpubmed-author:KuoZ FZFlld:pubmed
pubmed-article:14695221pubmed:authorpubmed-author:HongFengFlld:pubmed
pubmed-article:14695221pubmed:authorpubmed-author:RossGordon...lld:pubmed
pubmed-article:14695221pubmed:authorpubmed-author:HansenRichard...lld:pubmed
pubmed-article:14695221pubmed:authorpubmed-author:AllendorfDani...lld:pubmed
pubmed-article:14695221pubmed:authorpubmed-author:BaranJarek...lld:pubmed
pubmed-article:14695221pubmed:authorpubmed-author:OstroffGary...lld:pubmed
pubmed-article:14695221pubmed:issnTypePrintlld:pubmed
pubmed-article:14695221pubmed:day15lld:pubmed
pubmed-article:14695221pubmed:volume63lld:pubmed
pubmed-article:14695221pubmed:ownerNLMlld:pubmed
pubmed-article:14695221pubmed:authorsCompleteYlld:pubmed
pubmed-article:14695221pubmed:pagination9023-31lld:pubmed
pubmed-article:14695221pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:meshHeadingpubmed-meshheading:14695221...lld:pubmed
pubmed-article:14695221pubmed:year2003lld:pubmed
pubmed-article:14695221pubmed:articleTitleBeta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.lld:pubmed
pubmed-article:14695221pubmed:affiliationJames Graham Brown Cancer Center and. Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky 40202, USA.lld:pubmed
pubmed-article:14695221pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14695221pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:14695221pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:14695221pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:12266entrezgene:pubmedpubmed-article:14695221lld:entrezgene
entrez-gene:16409entrezgene:pubmedpubmed-article:14695221lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695221lld:pubmed